DNA repair dysregulation from cancer driver to therapeutic target - PubMed (original) (raw)
Review
. 2012 Dec;12(12):801-17.
doi: 10.1038/nrc3399.
Affiliations
- PMID: 23175119
- DOI: 10.1038/nrc3399
Review
DNA repair dysregulation from cancer driver to therapeutic target
Nicola J Curtin. Nat Rev Cancer. 2012 Dec.
Abstract
Dysregulation of DNA damage repair and signalling to cell cycle checkpoints, known as the DNA damage response (DDR), is associated with a predisposition to cancer and affects responses to DNA-damaging anticancer therapy. Dysfunction of one DNA repair pathway may be compensated for by the function of another compensatory DDR pathway, which may be increased and contribute to resistance to DNA-damaging chemotherapy and radiotherapy. Therefore, DDR pathways make an ideal target for therapeutic intervention; first, to prevent or reverse therapy resistance; and second, using a synthetic lethal approach to specifically kill cancer cells that are dependent on a compensatory DNA repair pathway for survival in the context of cancer-associated oxidative and replicative stress. These hypotheses are currently being tested in the laboratory and are being translated into clinical studies.
Similar articles
- Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer.
Curtin NJ. Curtin NJ. Br J Pharmacol. 2013 Aug;169(8):1745-65. doi: 10.1111/bph.12244. Br J Pharmacol. 2013. PMID: 23682925 Free PMC article. Review. - Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H, Ui A, Shiotani B, Zou L, Yasui A, Kohno T. Ogiwara H, et al. Carcinogenesis. 2013 Nov;34(11):2486-97. doi: 10.1093/carcin/bgt240. Epub 2013 Jul 3. Carcinogenesis. 2013. PMID: 23825154 - Inhibition of DNA Repair in Cancer Therapy: Toward a Multi-Target Approach.
Lodovichi S, Cervelli T, Pellicioli A, Galli A. Lodovichi S, et al. Int J Mol Sci. 2020 Sep 12;21(18):6684. doi: 10.3390/ijms21186684. Int J Mol Sci. 2020. PMID: 32932697 Free PMC article. Review. - Targeting homologous recombination repair defects in cancer.
Evers B, Helleday T, Jonkers J. Evers B, et al. Trends Pharmacol Sci. 2010 Aug;31(8):372-80. doi: 10.1016/j.tips.2010.06.001. Epub 2010 Jul 2. Trends Pharmacol Sci. 2010. PMID: 20598756 Review. - DNA damage response--a double-edged sword in cancer prevention and cancer therapy.
Tian H, Gao Z, Li H, Zhang B, Wang G, Zhang Q, Pei D, Zheng J. Tian H, et al. Cancer Lett. 2015 Mar 1;358(1):8-16. doi: 10.1016/j.canlet.2014.12.038. Epub 2014 Dec 17. Cancer Lett. 2015. PMID: 25528631 Review.
Cited by
- Crosstalk between BER and NHEJ in XRCC4-Deficient Cells Depending on hTERT Overexpression.
Sergeeva SV, Loshchenova PS, Oshchepkov DY, Orishchenko KE. Sergeeva SV, et al. Int J Mol Sci. 2024 Sep 27;25(19):10405. doi: 10.3390/ijms251910405. Int J Mol Sci. 2024. PMID: 39408734 Free PMC article. - DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors.
Amodio V, Vitiello PP, Bardelli A, Germano G. Amodio V, et al. Br J Cancer. 2024 Sep 13. doi: 10.1038/s41416-024-02848-8. Online ahead of print. Br J Cancer. 2024. PMID: 39271762 Review. - The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors.
Incorvaia L, Bazan Russo TD, Gristina V, Perez A, Brando C, Mujacic C, Di Giovanni E, Bono M, Contino S, Ferrante Bannera C, Vitale MC, Gottardo A, Peri M, Galvano A, Fanale D, Badalamenti G, Russo A, Bazan V. Incorvaia L, et al. NPJ Precis Oncol. 2024 Sep 5;8(1):190. doi: 10.1038/s41698-024-00672-0. NPJ Precis Oncol. 2024. PMID: 39237751 Free PMC article. Review. - The Effects of Gynecological Tumor Irradiation on the Immune System.
Romero Fernandez J, Cordoba Largo S, Benlloch Rodriguez R, Gil Haro B. Romero Fernandez J, et al. Cancers (Basel). 2024 Aug 9;16(16):2804. doi: 10.3390/cancers16162804. Cancers (Basel). 2024. PMID: 39199577 Free PMC article. Review. - Landscape of homologous recombination deficiency in gastric cancer and clinical implications for first-line chemotherapy.
Ichikawa H, Aizawa M, Kano Y, Hanyu T, Muneoka Y, Hiroi S, Ueki H, Moro K, Hirose Y, Miura K, Shimada Y, Sakata J, Yabusaki H, Nakagawa S, Kawasaki T, Okuda S, Wakai T. Ichikawa H, et al. Gastric Cancer. 2024 Aug 7. doi: 10.1007/s10120-024-01542-1. Online ahead of print. Gastric Cancer. 2024. PMID: 39110344
References
- Biochem Pharmacol. 2012 Jul 15;84(2):137-46 - PubMed
- Cell Cycle. 2004 Sep;3(9):1177-81 - PubMed
- Clin Cancer Res. 2011 Apr 1;17(7):2035-43 - PubMed
- J Natl Cancer Inst. 2000 Apr 5;92(7):564-9 - PubMed
- Mol Cancer Ther. 2007 Mar;6(3):945-56 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources